Program
selinexor
Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.
Drug pageSelinexor: every studyMany companies study it; this page follows only the 40 they lead. All 163 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Karyopharm Therapeuticsits history only | 317 open or running | phase 3since Oct 13, 2015 | May 16, 2012 | Dec 2026phase 3 · NCT04442022 |
| Antengeneits history only | 40 open or running | phase 2since Apr 30, 2019 | Apr 30, 2019 | none ahead |
| Oncotherapeuticsits history only | 22 open or running | phase 1since Aug 12, 2020 | Aug 12, 2020 | Apr 1, 2027phase 1 · NCT06225310 |
| AbbVieits history only | 11 open or running | phase 3since Nov 28, 2023 | Nov 28, 2023 | Dec 2027phase 3 · NCT06158841 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Aug 13, 2025 | Aug 13, 2025 | Dec 2027phase 3 · NCT07138209 |
| Sarah Cannon Research Instituteits history only | 11 open or running | phase 2since Mar 1, 2021 | Mar 1, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qilu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 13, 2025First study: phase 3 study in RecurrenceFirst studyNCT07138209 · 228 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in RecurrenceNCT07138209
TargetBeta
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule
Other programs on XPO1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB3107 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
The one study Qilu Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07138209Recurrence · China | 3 | Recruiting | Dec 2027 | 228 |
How it is read
Names in the registry
- “Selinexor”, 32 entries
- “Selinexor (combination therapy)”, 3 entries
- “Selinexor 40 mg”, 2 entries
- “Selinexor 60 mg”, 2 entries
- “ATG-010”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Primary Myelofibrosis, 3 studies
- Endometrial Neoplasms, 2 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.